Failure to Warn: What Dupixent Lymphoma Lawsuits Allege

The Claim at the Center of the Dupixent Litigation

If you have read anything about the Dupixent (dupilumab) lawsuits, you have probably seen the phrase failure to warn. Reported filings, described in coverage from outlets such as AboutLawsuits.com and LawyersandSettlements.com, allege that Sanofi and Regeneron did not adequately warn patients or prescribing physicians about a possible association between Dupixent and cutaneous T-cell lymphoma (CTCL), including mycosis fungoides and Sézary syndrome.

That is a specific legal theory — not a general statement that the drug is harmful. Understanding the difference matters, because it shapes what a claim has to show, what records matter, and who might have a claim at all.

This litigation is early. Very little has been established as fact. Everything below is described as an allegation under examination or as general medical background, and none of it should be read as a finding that Dupixent causes cancer.

What a Failure-to-Warn Claim Actually Says

Under product liability law in most states, a manufacturer can be held responsible not only for how a product is made, but for what it tells people about the product’s risks. A failure-to-warn claim generally alleges that:

• The manufacturer knew, or reasonably should have known, of a risk associated with the product
• The warning provided did not adequately convey that risk
• An adequate warning would have changed the decision of the prescriber or the patient
• The injury resulted from that inadequate warning

For prescription drugs, most states apply the learned intermediary doctrine: the manufacturer’s duty to warn generally runs to the prescribing physician, who then counsels the patient. That is why the reported Dupixent complaints put so much weight on what dermatologists were told. Coverage summarized by AboutLawsuits.com describes at least one lawsuit alleging that information about a possible cancer link was withheld from doctors and users.

General background on how these doctrines are framed is available through the Legal Information Institute at Cornell Law School.

Two Distinct Allegations, Not One

A point that is easy to miss: the reported Dupixent complaints advance two separate limbs, and they are not interchangeable.

First, that Dupixent may cause or accelerate a cutaneous T-cell lymphoma in someone who did not have one. Reported filings described by AboutLawsuits.com include claims that a CTCL or mycosis fungoides diagnosis followed Dupixent treatment for eczema or atopic dermatitis.

Second, that Dupixent may mask the early symptoms of a lymphoma the patient already had — quieting the rash, the itching, and the visible skin changes that would otherwise prompt a biopsy — and thereby delay diagnosis. One reported lawsuit, as described in that same coverage, alleges the drug caused or rapidly progressed an existing cancer.

The practical consequence of the second limb is significant: a diagnosis that predates Dupixent does not automatically disqualify someone. We wrote about this in more depth in our post on the masking theory, Diagnosed Before Dupixent? The Masking Claim Explained.

Both limbs are allegations. Neither has been established, and no court has found either to be true.

Why Early CTCL Is Hard to Tell From Eczema

The overlap between severe eczema and early cutaneous T-cell lymphoma is a documented clinical challenge that long predates this litigation. According to the National Cancer Institute, mycosis fungoides — the most common form of CTCL — often begins with patches or plaques that can resemble eczema or psoriasis, and the diagnosis is frequently made only after repeated biopsies over months or years.

That diagnostic difficulty is background context, not proof of anything. It explains why patients in this situation often have long dermatology histories, multiple skin biopsies, and more than one working diagnosis before a lymphoma is identified. It also explains why plaintiffs’ lawyers pay close attention to the sequence and timing of those records.

Peer-reviewed research on dupilumab and lymphoma is being published and debated; searches through PubMed will surface case reports and analyses on both sides. Published studies to date describe associations and case observations, not proven causation, and the scientific question remains genuinely open.

What the FDA Has and Has Not Done

Be careful with what you read online here. We are not aware of any recall of Dupixent, and we will not characterize the drug’s labeling as containing a warning it may not contain.

What we can say accurately: adverse event reporting, labeling, and post-market safety review are all handled by the U.S. Food and Drug Administration, and any change to a drug’s label or safety communications would appear through the agency’s own channels. If you want to know the current state of Dupixent’s labeling, the FDA’s own site is the authoritative source — not a law firm page, including ours.

A lawsuit alleging inadequate warning is not the same as a regulatory finding. The two proceed on separate tracks.

What Centralization Did — and Did Not — Decide

Dupixent CTCL cases filed in federal courts have been centralized into a multidistrict litigation, a step reported by AboutLawsuits.com and handled through the Judicial Panel on Multidistrict Litigation.

It is worth stating plainly what that means: MDL centralization is a case-management decision, not a ruling on the merits. The panel consolidates cases that share common questions of fact so that discovery and pretrial motions can be handled once instead of dozens of times. It says nothing about whether Dupixent causes lymphoma, whether the warnings were adequate, or whether any plaintiff will recover anything.

Defendants have not been found liable. The causation question has not been tried. Our post on what MDL consolidation means walks through the mechanics in more detail.

The Records That Tend to Matter

In a failure-to-warn case, the paper trail does most of the work. The categories that typically matter include:

• Dermatology records showing the eczema or atopic dermatitis diagnosis that led to Dupixent
• Prescription and pharmacy records establishing when treatment started and how long it continued
• Pathology reports from every skin biopsy, including any that were read as inconclusive
• The lymphoma diagnosis itself, including staging and any TCR gene rearrangement or flow cytometry results
• Treatment records for the cancer — phototherapy, topical therapy, systemic therapy, or chemotherapy

If you do not have these, that is normal and not a barrier. They live with your treating providers and can be requested. You are not expected to assemble a medical file before speaking with anyone.

Realistic Expectations About Timing

Early litigation moves slowly, and honest expectations are better than optimistic ones. Before any case reaches a jury, the parties generally work through document discovery, expert reports on general causation, and pretrial motions — a process that commonly takes years in pharmaceutical MDLs.

We cannot tell you what any claim is worth, whether there will be a settlement, or when. Anyone who does is guessing. What we can tell you is that statutes of limitations run regardless of how early the litigation is, and those deadlines vary by state and are often measured from the date of diagnosis or from when the connection reasonably should have been discovered.

Who Might Want to Look Into This

Generally speaking, the people looking at these claims were treated with Dupixent for eczema or atopic dermatitis and were later diagnosed with a cutaneous T-cell lymphoma — mycosis fungoides, Sézary syndrome, or another CTCL subtype. Because of the masking limb described above, people whose lymphoma diagnosis came before or during Dupixent treatment may also have something worth reviewing.

Having a claim reviewed does not commit you to filing one, and a review costs nothing. You can learn more on our Dupixent lymphoma practice page.

Take the Next Step

If you or someone in your family was treated with Dupixent and later received a cutaneous T-cell lymphoma diagnosis, you can have the timeline reviewed by an attorney at no cost and with no obligation. We will tell you honestly what we see, including when we think there is nothing there.

Request a free case review to have your situation evaluated.

This article is for general information only and is not legal or medical advice. No outcome is promised or implied. The allegations described here have not been proven, and no court has determined that Dupixent causes cutaneous T-cell lymphoma.